Leah Goodman

Chief Executive Officer @ Biointelect Pty Ltd

About

I am an experienced country and regional business leader in Asia and Australasia, having successfully developed businesses and teams to high performance through establishing clarity of goal and engaged teams, high performing leadership teams, and innovative business model transformations to achieve revenue and EBIT goals in ANZ and Asian countries (Japan, South Korea, Malaysia, Singapore, Australia, New Zealand). I have a unique combination of Consultancy experience, Multinational commercial leadership, Scale up business leadership, Policy and Market access leadership, and have experience building diverse business models based on understanding stakeholder motivation. This diversity extends to commercialation from pre clinical to market capabilities, including Clinical Trials of all stages. I have advanced GMP manufacturing experience and novel technology including RNA and CAR-T experience. My career spans diverse Pharmaceutical innovative platforms, Consumer healthcare, Nutraceuticals and Vaccines. I have a reputation for business achievement and the ability to achieve financial goals through business transformation, whilst improving the engagement of the employee base and developing high performing leadership teams. In all roles I have established an aligned company strategy with clarity of objectives and personal success measures (KPI dashboard mindset), partnered with a focus on team and individual development investment, which has led to high employee engagement across the business. Through Policy and Market Access leadership I have shaped Policy in Multiple countries and established innovative access models to expedite medicine access to patients. Through my strong access market understanding, I have deep success in defining reimbursed routes to market to expedite patient access. Through experience with different customer interfacing business models, sizes and life cycle stages, I have strong hands on operational skills whilst maintaining the agility to engage and contribute at strategic level with innovative approaches whilst ensuring global alignment and stakeholder engagement. With strong and diverse experience in the life science sector I have worked across OTC, generic medicines, Cell and Gene therapies (including manufacturing), Immuno-oncology, Device-medicine treatments, Radiopharmaceuticals, Vaccines, Rare Diseases, Hospitals and Primary care. This has resulted in strong success in novel therapy launch access models and customer engagement models exacerbating update and market leadership prescription.

Country

Australia

City

Sydney

Industry

Biotechnology

Skill

Government policy, Stakeholder Engagement, Business Alliance Development, Alliance Creation, Product Development, Radiopharmaceuticals, Cell Biology, Generics, OTC Markets, Consumer Healthcare, Startup Development, Clinical Research, Research and Development (R&D), Incubators, Problem Solving, Financial Performance, Employee Engagement, Corporate Financial Reporting, Workplace Culture, Public Policy

Experience

Chief Executive Officer

Biointelect Pty Ltd

2023-11 - Present · 2 yrs 11 mos

Sydney, New South Wales, Australia

- Building a life science consultancy business to medium scale through organic and inorganic investment growth strategies. Building strong EBIT to enable growth strategy and 3rd party equity partnership. - active engagement with investors and partners for business expansion - through MRFF grant funding - establishment and execution of an Incubator in vaccines/ immunological diseases. - global (Aust, Asian and US) launch commercialisation projects for Australian, US and Asian biotec - expansion of a full service CRO, initiating clinical trials from early phase - Asia and US geographic expansion - CGT experience across manufacturing, translation and commercialisation - RNA ecosystem shaping aligned with research, clinical trials and manufacturing - registration and pricing for access in HTA markets across Vaccines; Radiopharma / Theranostics and Antibody Conjugates; Rare diseases; Oncology; Neuroscience; Fertility; Metabolic Diseases; - Engagement with State Govt, Universities, Precincts for business strategy and economic impact - Biotech start up for preclinical product positioning, regulatory strategy, clinical trial execution, commercialisation - Policy shaping through white paper development to enable access and market development including economic impact of R&D

Chief Executive Officer

Biointelect Venturer

2025-5 - Present · 1 yr 5 mos

Sydney, New South Wales, Australia

BioIntelect Venturer is an MRFF funded incubator for vaccines, immunotherapeutics for preventative medicine. As CEO of Biointelect I am recruiting a team (headed by a General Manager) and establishing this incubator with the aim of supporting early phase research based SME commercialisation.

Non Executive Director

Providence Therapeutics

2026-1 - Present · 9 mos

Sydney, New South Wales, Australia

Providence Therapeutics is a clinical‑stage mRNA company focused on differentiated vaccines and immunotherapies, with programs spanning oncology and infectious diseases. Its proprietary mRNA platform is designed for potency, speed, and scalability. The company is a globally competitive innovator in next‑generation RNA medicines.

Australian Resident Non Executive Director

Orna Therapeutics

2025-10 - Present · 1 yr

Sydney, NSW

Orna therapeutics is developing the leading circular RNA technology platform (oRNA®) and lipid nanoparticle (LNP) delivery solutions – significantly expanding the therapeutic possibilities of circular RNA and pioneering the next chapter of safe and effective in vivo therapies.

NSW Leadership Committee

AusBiotech

2023-11 - Present · 2 yrs 11 mos

Sydney, Australia

- Development of State strategic plan and operational direction for Biotech ecosystem in NSW as part of a wider national agenda for biotechnology enablement in Australia

Commercialisation Committee

BioNSW

2024-10 - Present · 2 yrs

Australia

BioNSW is dedicated to harnessing the full potential of the NSW Life Sciences sector and catalysing innovation, investment, skills and jobs for economic growth, prosperity and a healthier community.

Member

Chief Executive Women (CEW)

2022-11 - Present · 3 yrs 11 mos

Catalyst Policy and Advocacy Working Group

Medicines Australia: Catalyst - Australia's Cell and Gene Therapy collaboration

2024-1 - 2025-12 · 2 yrs

Australia

- Federal and State policy and advocacy strategy formation and executional planning for Cell and Gene therapies enablement in Australia - Committee tenure completed with AusBiotech making changes in strategy

Advisory Board - ARCS Executive Signature Program

ARCS Australia

2021-7 - 2025-1 · 3 yrs 7 mos

Sydney, New South Wales, Australia

Managing Director Australia & New Zealand

Bristol Myers Squibb

2022-9 - 2023-11 · 1 yr 3 mos

Melbourne, Victoria, Australia

- Business of 400 local staff / Gross sales approx $1b AUD - Built a high performance culture - overachieved revenue and EBIT goals. - active partnership with 3rd parties to drive investment and revenue growth - established united Vision which fed a strong and prioritised strategy which supported focused objectives and achievement. Resulted in an engagement plan with metrics achievement - significant launch of new innovative therapies in MS/neurology, dermatology, cardiovascular, immunooncology, immunotherapies, rare diseases - Alliance management / new partnership development - CAR-T strategic market introduction planning - Drove Industry Market policy change in Market Attractiveness and investment; Clinical Trials; Novel Access models for small populations - advocated successfully for clinical trial federal budget investment - leadership team development as a high performing team with strong development of team members and improved engagement and functionality of team performance